Evidence map›Paper›PMID 41028859›Full record

ArticleScientific reports2025

Faricimab at 6 and 12 mg reduces pigment epithelium detachment in treatment-resistant macular neovascularization: an OCT and AI analysis.

Ines D Nagel, Melanie D Tran, Haochen Zhang, Lingyun Cheng, Anna Heinke, Nehal N Mehta, Dirk-Uwe Bartsch, Fritz G P Kalaw, Mohamed Morsy, Arthur J Mueller and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ines D NagelJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Melanie D TranJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Haochen ZhangDivision of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, CA, 92093, USA.
Lingyun ChengJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Anna HeinkeJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Nehal N MehtaJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Dirk-Uwe BartschJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Fritz G P KalawJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Mohamed MorsyJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.
Arthur J MuellerDepartment of Ophthalmology, University Hospital Augsburg, 86156, Augsburg, Germany.
William R FreemanJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92093, USA. wrfreeman@health.ucsd.edu.

Funding

Mechanistic-Based Non-Invasive Assessment of Retinal Damage in HAART EraR01EY016323 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BARTSCH, DIRK-UWE G · 2006 to 2020
$5.0M
National Institutes of Health Bridge2AI Project OT2OD032644NIH grant R01EY016323NIH Grant 5R01EY033847UCSD Vision Research Center Core Grant P30EY022589
6 · The paper itself

Abstract

Macular neovascularization (MNV) in age-related macular degeneration (AMD) remains a therapeutic challenge, especially in eyes resistant to conventional anti-VEGF therapy. This study evaluates the anatomical and functional response to Faricimab in patients with persistent fluid despite intensified Aflibercept treatment and explores potential benefits of dose escalation. This cross-sectional study included 25 eyes from 23 patients with active MNV resistant to standard anti-VEGF therapy. All had persistent fluid on OCT despite monthly injections and received off-label double-volume Aflibercept 4 mg (0.1 ml) for at least three doses. Eyes with persistent fluid were switched to Faricimab 6 mg. In non-responders, Faricimab was further escalated to 12 mg (0.1 ml). Retinal fluid volumes and pigment epithelium detachment (PED) were analyzed using AI-based OCT segmentation. MNV activity was assessed using AI-based OCTA analysis. Faricimab 6 mg significantly reduced PED volume (p < 0.05), especially after the first two injections. However, changes in intraretinal and subretinal fluid were not significant. In the Faricimab 12 mg subgroup, no additional anatomical benefit was observed. OCTA showed a trend toward reduced vascular activity after switching to Faricimab 6 mg, but no further change with dose escalation. In MNV eyes resistant to high-dose Aflibercept, Faricimab 6 mg provides meaningful anatomical improvement, particularly in PED volume. However, escalating Faricimab to 12 mg offers no additional benefit, suggesting therapeutic saturation at the standard dose.

Indexed as

Angiogenesis InhibitorsMacular DegenerationRetinal DetachmentRetinal Pigment EpitheliumAgedAged, 80 and overAntibodies, BispecificCross-Sectional StudiesFemaleHumansIntravitreal InjectionsMaleMiddle AgedReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceafliberceptAngiogenesis InhibitorsAntibodies, BispecificfaricimabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAge-related macular degenerationAI-based image analysisanti-VEGF resistanceChoroidal neovascularizationDose escalationFaricimab

Identifiers

PMID41028859
PMCPMC12484819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.